Altima is primarily applied in addressing conditions characterized by significant physiological stress within the chest. The medication is relevant across therapeutic domains involving distressing symptoms associated with these conditions.

Treatment of Advanced Non-Squamous Lung Cancer

This therapeutic domain covers the use of Altima (Pemetrexed) for managing locally advanced or metastatic non-small cell lung cancer (NSCLC) that is specifically not the squamous type. It is applied when conditions present with systemic or localized discomfort, such as for newly diagnosed disease (often combined with other agents) or when the cancer is recurrent after prior treatment.

It is used to manage locally advanced or metastatic non-squamous non-small cell lung cancer and for malignant pleural mesothelioma. The treatment may assist in managing the progression of the disease and supports general well-being during symptomatic phases.

“This treatment is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall burden of symptoms.”

Strategic Use in Maintenance and Mesothelioma Control

Altima is also a relevant option for managing malignant pleural mesothelioma, a condition marked by increased physiological stress. Furthermore, it is commonly used alone as maintenance treatment for NSCLC. By providing ongoing therapeutic support, the medication may assist in managing or supporting disease stability and contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Systemic Malignant Activity The medication is applied when conditions involve chronic systemic processes where functional stability becomes affected.

The eligibility for using Altima (pemetrexed) is strictly defined by regulatory authorities based on a patient's pre-existing conditions and physical status.

Populations for Whom Use is Prohibited (Contraindications)

• Hypersensitivity: Use is absolutely contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed or any of its excipients.
• Lactation and Pregnancy: Breastfeeding women must not use the medicine. Use during pregnancy is restricted because the drug can cause fetal harm, requiring females of reproductive potential to use effective contraception.
• Vaccine: The concomitant use of yellow fever vaccine is contraindicated.

Condition-Based and Organ Function Restrictions

• Severe Renal Impairment: Altima must not be administered when a patient's creatinine clearance ( CrCl) is less than 45 mL/min, as there is insufficient data to support safe use.
• Hematologic Status: Treatment cannot begin until the absolute neutrophil count ( ANC) is ge 1500 cells/mm^3 and the platelet count is ge 100,000 cells/mm^3.
• Tumor Type: The medicine is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.

Age-Specific Eligibility

• Pediatric Population: Use is not recommended in children or adolescents, as the safety and efficacy have not been established in the context of the approved indications.
• Older Adults: No special dose adjustments are required for patients 65 years of age or older based on age alone, provided other eligibility criteria are met.

Interactions with other medicines and products

Pharmacokinetic Interactions and Clearance

The official interaction profile for Altima (pemetrexed) is heavily influenced by its renal excretion pathway. The concomitant use of nephrotoxic drugs or substances that are tubularly secreted by the kidney may result in delayed clearance of Pemetrexed, increasing systemic exposure. Specifically, Ibuprofen is documented to reduce Pemetrexed clearance and increase systemic exposure (AUC) by approximately 20%.

Timing-Based Restrictions

Mandatory timing separation rules for all Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are required for patients with mild to moderate renal impairment (creatinine clearance 45 to 79 mL/min). Short-half-life NSAIDs, including Ibuprofen and high-dose acetylsalicylic acid (>1.3 g daily), must be avoided for 2 days before, the day of, and 2 days following Altima administration. NSAIDs with long elimination half-lives require interruption for a longer period of at least 5 days prior to administration. The interaction severity is explicitly dependent upon the patient’s renal function.

Contraindicated Combinations and Non-Interacting Agents

The European Medicines Agency (EMA) formally classifies co-administration with the Yellow Fever Vaccine as contraindicated. Conversely, official regulatory documents state that the pharmacokinetics of Pemetrexed are not affected by low-dose acetylsalicylic acid, Folic Acid, or Vitamin B12. The overall structure emphasizes renal competition as the primary pharmacokinetic constraint, alongside the formal classification of prohibited combinations.

Disruption of Folate-Dependent Nucleotide Biosynthesis

Pemetrexed is a folate analog that acts as a multitargeted inhibitor of key enzymes in the cellular metabolic pathway. Its main targets include Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT). By competitively blocking these enzymes, the drug prevents the production of essential precursors—specifically thymidylate and purines—required for the synthesis and repair of DNA and RNA. This fundamental disruption of genetic material synthesis leads to nucleotide pool depletion, which initiates the cascading effect of the drug's mechanism.

---

Selective Intracellular Activation and Cell Cycle Failure

For the drug to achieve greater intracellular activity, it undergoes polyglutamation inside the cell, a process catalyzed by the enzyme Folylpolyglutamate Synthetase (FPGS). This activation traps the drug within the cell and increases its inhibitory potency against the target enzymes, particularly in rapidly dividing cell populations. The resulting profound DNA damage and replication failure trigger apoptosis (programmed cell death) and cell cycle arrest, primarily impacting cells undergoing active proliferation. This mechanism results in the inhibition of cellular proliferation.

How to Use Altima: Official Administration Guidelines

Altima (Pemetrexed disodium) is administered exclusively as a high-level, procedural treatment defined by specific regulatory guidelines. The medicine is not taken orally; its sole official route of administration is as an Intravenous (IV) infusion.

Dosing Schedule and Frequency

The standard adult dose is 500 mg per square meter of body surface area (500 mg/m^2 BSA). This dose is given on Day 1 of a fixed 21-day cycle. Subsequent cycles may be delayed or the dose reduced if predefined criteria for blood counts and patient tolerability are not met. Treatment typically continues until the treating physician determines the patient meets criteria for discontinuation, such as disease progression.

Required Pretreatment and Administration Constraints

Proper use of Altima requires the administration of several concomitant medications. Patients must follow a specific regimen of oral Folic Acid, an intramuscular injection of Vitamin B12, and oral or IV dexamethasone beginning before the first Pemetrexed dose and continuing throughout the course.

Procedural Constraints

The IV infusion must be administered over a strict 10-minute period. Furthermore, the medicine is prohibited for use in patients whose creatinine clearance (CrCl) is less than 45 mL/min. Prior to each cycle, blood counts, including the Absolute Neutrophil Count and platelet count, must be monitored to determine fitness for administration and potential dose adjustment.

Research Evidence / Overview of Studies for Altima (Pemetrexed)

---

Evidence for Use in Malignant Pleural Mesothelioma

Research for Altima in malignant pleural mesothelioma (MPM) focused on a pivotal, randomized, multi-center Phase III trial. These studies compared a Pemetrexed combination regimen with a platinum agent against a control group. Researchers focused on tracking outcomes related to Overall Survival (OS) and the Time to Progressive Disease (TTP). The populations studied were chemotherapy-naive adults diagnosed with unresectable MPM who met specific performance status criteria. The findings describe patterns observed in the studies related to the measurement of patient survival and the evaluation of the time to progressive disease across the groups studied. What remains uncertain is the data available for patients with a poor performance status, and comparative evidence with platinum agents other than cisplatin is limited.

---

Evidence for Use in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Research on Pemetrexed as Initial Treatment for Advanced Disease

Evidence for using the Pemetrexed combination regimen as an initial treatment for advanced non-squamous NSCLC is documented in several large-scale Randomized Controlled Trials (RCTs). These studies explored how Pemetrexed compared with other established chemotherapy combinations. The main outcomes research examined included Overall Survival (OS) and Progression-Free Survival (PFS). The research describes that the use of Pemetrexed in the squamous cell lung cancer subtype was studied and found not to apply in the core trials.

Research on Pemetrexed as Continuation Maintenance Therapy

The evidence for Pemetrexed as a continuation maintenance therapy is based on a pivotal, double-blind, randomized Phase III trial that compared continued use of Altima with a placebo control. This research was conducted for patients whose non-squamous NSCLC had not progressed after their initial course of chemotherapy. Studies monitored Progression-Free Survival (PFS) as the primary endpoint. There are limited direct comparative data for Pemetrexed versus certain newer agents now used in the maintenance setting.

Common questions about Altima (FAQ)

---

Q: What is the active ingredient in Altima, and how does it work to treat [disease]?

Altima's active ingredient is Raptoril, which is classified as a Selective Beta-Blocker. Official product information states that it works by targeting and blocking specific receptors in the body. This action helps to relieve strain on the heart and may lower elevated blood pressure, according to regulatory sources.

---

Q: Does Altima cure [disease], or just manage symptoms?

Regulatory documents indicate that Altima is intended for the management of symptoms and for improving the long-term outlook for patients with [disease]. Official product information describes its role as helping manage and control symptoms associated with chronic conditions, rather than being a cure.

---

Q: How long until I feel the effects of Altima after starting treatment?

Initial effects, such as changes in blood pressure, may be observed within a few hours, but the full therapeutic benefit can take longer. Official information indicates that achieving the full clinical effect, especially for chronic heart conditions, may require dose adjustment over several weeks.

---

Q: Can I stop taking Altima suddenly if I feel better?

Official regulatory instructions caution against abruptly discontinuing Altima, especially for patients with certain underlying conditions. Suddenly stopping treatment can potentially lead to a worsening or return of symptoms. Any changes to the treatment plan should be discussed with and monitored by a healthcare professional.

---

Q: Is Altima safe to use if I have asthma?

According to regulatory documents, Altima is generally contraindicated (not recommended) for individuals with severe bronchial asthma or certain other chronic obstructive lung conditions. For patients with less severe respiratory issues, the official documentation states the medication must be used only with caution and close supervision by a doctor.

The medicine Altima (Pemetrexed disodium) is supplied as a powder and must be handled and stored according to specific regulatory requirements for antineoplastic agents.

Storage Conditions

Product Form	Required Temperature	Stability Constraint
Unreconstituted Powder	Controlled room temperature (20 C to 25 C)	Store in original container.
Reconstituted/Diluted Solution	Refrigerated conditions (2 C to 8 C)	Must be used within 24 hours.

Handling and Disposal

Altima is classified as a hazardous drug; therefore, its preparation and handling must follow special procedures for cytotoxic agents. The product must be kept out of the sight and reach of children. Unused portions and waste material must not be thrown away with household waste or wastewater. Disposal must be carried out in accordance with local cytotoxic waste regulations.